Clinical Trial

Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts

Study acronym: EBGraft
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase I/II clinical trial aims to treat 3 adult subjects with Recessive Dystrophic Epidermolysis Bullosa, expressing residual C7 levels, by genetically corrected autologous skin equivalent grafts on selected areas (up to 300 cm2).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-12-04; most recent amendment 2026-02-10.
Status change: Enrolling by Invitation → Active, Not Recruiting 2021-10-18
Trial Details
NCT Number NCT04186650
Lead Sponsor Institut National de la Santé Et de la Recherche Médicale, France
Conditions Epidermolysis Bullosa Dystrophica, Recessive
Enrollment 3 participants
Start Date 2020-01-10
Primary Completion 2027-06-09 (estimated)
Study Completion 2027-06-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-12